{"schema_version":"secwatch.filing_event.v1","accession":"0001600620-23-000030","form_type":"8-K","ticker":"AUPH","cik":"0001600620","company_name":"Aurinia Pharmaceuticals Inc.","filed_at":"2023-08-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.502625+00:00","generated_at":"2026-06-11T06:15:12.109307+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Aurinia appoints Dr. Karen Smith and Jeffrey A. Bailey to Board; Dr. Daniel G. Billen named Chair","bullets":["Dr. Karen Smith and Jeffrey A. Bailey joined Aurinia's Board effective August 18, 2023, bringing decades of biopharma leadership experience.","Dr. Daniel G. Billen, board member since 2019, appointed Chair of the Board of Directors.","Both new directors have experience with successful sales, mergers, and partnerships, relevant to the ongoing strategic review process.","Dr. Smith has served on boards of several acquired companies (Forward Pharma, Sucampo, Acceleron, Antares Pharma).","Mr. Bailey has held CEO and Chairman roles, including Chairman of Tekla Capital Management since 2020."],"urls":{"canonical":"https://secwatch.observer/filing/0001600620-23-000030","json":"https://secwatch.observer/filing/0001600620-23-000030.json","markdown":"https://secwatch.observer/filing/0001600620-23-000030.md","text":"https://secwatch.observer/filing/0001600620-23-000030.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1600620/000160062023000030/0001600620-23-000030-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1600620/000160062023000030/auph-20230818.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T06:15:12.109307+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"47e58ec4a9","claim":"Jeffrey A. Bailey was appointed as Director at Aurinia Pharmaceuticals Inc..","evidence_excerpt":"On August 21, 2023, Aurinia Pharmaceuticals Inc. (the Company) issued a press release announcing the appointments of Dr. Karen Smith and Jeffrey A. Bailey to the Board of Directors of the Company (the Board) effective August 18, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1600620/000160062023000030/0001600620-23-000030-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"ae93a7b634","claim":"Dr. Karen Smith was appointed as Director at Aurinia Pharmaceuticals Inc..","evidence_excerpt":"On August 21, 2023, Aurinia Pharmaceuticals Inc. (the Company) issued a press release announcing the appointments of Dr. Karen Smith and Jeffrey A. Bailey to the Board of Directors of the Company (the Board) effective August 18, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1600620/000160062023000030/0001600620-23-000030-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}